
You are here
International scientific guidelines adopted in Australia
Related information
The TGA closely aligns its regulatory approaches to therapeutic products with those of comparable international regulatory counterparts wherever possible.
Technical data requirements for applications to register or vary the registration of medicines in Australia are closely aligned with requirements set out in relevant:
- European Union (EU) Guidelines
- Guidelines issued by the International Conference on Harmonisation (ICH) of Technical Requirements for Registration of Pharmaceuticals for Human Use
- Food and Drug Administration (USA)
International Guidelines are not limited to prescription medicines, but may also apply to OTC, complementary and some listed medicines. It is important that you review the relevant guidelines that are adopted in Australia prior to manufacturing and supplying a medicine.
While guidelines that are adopted in Australia are generally not mandated by legislation, they provide guidance to sponsors to assist them to meet the legislative requirements and any deviation from a Guideline relevant to an application to register or vary the registration of a medicine must be justified.
Prior to adopting any Guideline, the TGA undertakes an extensive process of internal and external consultations to ensure the Guideline is consistent with prevailing requirements in Australia. TGA publishes a searchable list of International Guidelines adopted in Australia. Please check for current consultations on proposed guidelines for adoption in Australia.
Please note: Where EU Guidelines adopted in Australia include references to EU legislation (including EC Directives and Regulations), the requirements contained in the referenced EU legislation are not applicable to the evaluation of medicines by the TGA.
International scientific guidelines adopted in Australia
Displaying 41 - 50 of 373
Overseas effective date: 1 Apr 2014
Guideline on Dossier Structure and Content for Pandemic Influenza Vaccine Marketing Authorisation Application (Revision)
Replaces: CPMP/VEG/4717/03 (Adopted by TGA 16 August 2004)
Categories: Biological medicines | Drug substance | Multidisciplinary | Vaccines (multidisciplinary) | Nonclinical | General (nonclinical)
Overseas effective date: 1 Jul 2005
Guideline on Adjuvants in Vaccines for Human Use
Categories: Biological medicines | Drug substance | Vaccines (drug substance) | Multidisciplinary | Vaccines (multidisciplinary)
Overseas effective date: 24 Feb 2014
Questions and answers on the withdrawal of the 'Note for guidance on single dose toxicity'
Replaces: 3BS1a Single Dose Toxicity
Categories: Nonclinical | Toxicology | Single-dose toxicity
Overseas effective date: 1 Apr 2006
Guideline on the Non-Clinical Documentation for Mixed Marketing Authorisation Applications
Categories: Nonclinical | General (nonclinical)
Overseas effective date: 1 May 2000
Note for Guidance on Pre-Clinical Pharmacological and Toxicological Testing of Vaccines
Categories: Nonclinical | General (nonclinical)
Overseas effective date: 1 May 2009
Guideline on the Specification Limits for Residues of Metal Catalysts or Metal Reagents
Categories: Quality | Impurities | Nonclinical | General (nonclinical) | Clinical efficacy and safety | General (clinical)
Overseas effective date: 24 Feb 2014
Questions and answers on the 'Guideline on the limits of genotoxic impurities'
Replaces: EMA/CHMP/SWP/431994/2007 Revision 2
Categories: Quality | Impurities | Nonclinical | Toxicology | Genotoxicity
Overseas effective date: 4 Sep 2002
Points to Consider on the Non-Clinical Assessment of the Carcinogenic Potential of Insulin Analogues
Categories: Nonclinical | Toxicology | Carcinogenicity
Overseas effective date: 5 Mar 2003
Note for Guidance on Carcinogenic Potential
Categories: Nonclinical | Toxicology | Carcinogenicity
Overseas effective date: 1 Feb 2018
Guideline on strategies to identify and mitigate risks for first-in-human and early clinical trials with investigational medicinal products
Categories: Clinical efficacy and safety | Clinical pharmacology and pharmacokinetics | Product-specific bioequivalence